USA: According to a new consensus statement, people with type 2 diabetes sustaining normal blood sugar levels for three months or more should be considered in remission. The statement by the American Diabetes Association (ADA), the Endocrine Society, the European Association for the Study of Diabetes and Diabetes UK was jointly published in Diabetes Care, the Journal of Clinical...
USA: According to a new consensus statement, people with type 2 diabetes sustaining normal blood sugar levels for three months or more should be considered in remission. The statement by the American Diabetes Association (ADA), the Endocrine Society, the European Association for the Study of Diabetes and Diabetes UK was jointly published in Diabetes Care, the Journal of Clinical Endocrinology & Metabolism, Diabetologia, and Diabetic Medicine, respectively.
About 10% of the U.S. population has diabetes, and these numbers continue to rise. People with type 2 diabetes can achieve "remission" by sustaining normal blood glucose levels for at least three months without taking diabetes medication. There is still a lot of uncertainty around how long remission will last and what factors are associated with a relapse. Continued follow-up with the healthcare team is warranted for ongoing monitoring of glucose changes and diabetes complications. The long-term effects of remission on mortality, heart health, and quality of life are not well understood
"Our international group of experts suggest an HbA1c (average blood glucose) level of less than 6.5% at least three months after stopping diabetes medication as the usual diagnostic criterion for diabetes remission," said statement author and Editor in Chief of the ADA's Diabetes Care, Matthew Riddle of Oregon Health & Science University in Portland, Ore. Riddle is chair of the Diabetes Remission Consensus writing group that developed the statement. "We also made suggestions for clinicians observing patients experiencing remission and discussed further questions and unmet needs regarding predictors and outcomes."
The authors developed the following criteria to help clinicians and researchers evaluate and study diabetes remission using more consistent terminology and methods:
1. Remission should be defined as a return of HbA1c to less than 6.5% that occurs spontaneously or following an intervention and that persists for at least three months in the absence of usual glucose-lowering pharmacotherapy.
2. When HbA1c is determined to be an unreliable marker of long-term glycemic control, fasting plasma glucose of less than 126 mg/dL (<7.0 mmol/L) or estimated HbA1c less than 6.5% calculated from continuous glucose monitoring values can be used as alternate criteria.
3. Testing of HbA1c to document a remission should be performed just prior to an intervention and no sooner than three months after initiation of the intervention or withdrawal of any glucose-lowering pharmacotherapy.
4. Subsequent testing to determine long-term maintenance of remission should be done at least yearly, together with the testing routinely recommended for potential complications of diabetes.
"Diabetes remission may be occurring more often due to advances in treatment," said Amy Rothberg of the University of Michigan in Ann Arbor, Mich. Rothberg represents the Endocrine Society as a member of the Diabetes Remission Consensus writing group. "More research is needed to determine the frequency, duration, and effects on short- and long-term medical outcomes of remission of type 2 diabetes using available interventions."
Reference:
"Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes," is published in the journal Diabetes Care.
DOI: https://care.diabetesjournals.org/content/early/2021/08/17/dci21-0034.article-info
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd